Anti-PD-1 antibodies potentiate anti-tumor immunity by blocking the PD-1 receptor on T-cells from interacting with its ligands, programmed death ligand-1 (PD-L1) and programmed death ligand-2, on tumor cells or antigen-presenting cells. Here, PDCD1LG2 is linked to neoplasm.